Research ExplorerPublicationsEffects of renal denervation on heart failure biomarkers and...

Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension

Standard

Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. / Neumann, Johannes Tobias; Ewen, Sebastian; Mortensen, Kai; Nef, Holger; Zeller, Tanja; Ojeda, Francisco; Sydow, Karsten; Mahfoud, Felix; Böhm, Michael; Hamm, Christian; Dörr, Oliver; Blankenberg, Stefan.

In: BIOMARK MED, Vol. 10, No. 8, 08.2016, p. 841-851.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Neumann, JT, Ewen, S, Mortensen, K, Nef, H, Zeller, T, Ojeda, F, Sydow, K, Mahfoud, F, Böhm, M, Hamm, C, Dörr, O & Blankenberg, S 2016, 'Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension', BIOMARK MED, vol. 10, no. 8, pp. 841-851. https://doi.org/10.2217/bmm-2016-0098

APA

Neumann, J. T., Ewen, S., Mortensen, K., Nef, H., Zeller, T., Ojeda, F., Sydow, K., Mahfoud, F., Böhm, M., Hamm, C., Dörr, O., & Blankenberg, S. (2016). Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. BIOMARK MED, 10(8), 841-851. https://doi.org/10.2217/bmm-2016-0098

Vancouver

Neumann JT, Ewen S, Mortensen K, Nef H, Zeller T, Ojeda F et al. Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. BIOMARK MED. 2016 Aug;10(8):841-851. https://doi.org/10.2217/bmm-2016-0098

Bibtex

@article{a9f70d81b47c48968fd58ea6260db86f,
title = "Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension",
abstract = "AIM: This multicenter study investigated the effect of renal denervation therapy (RDN) on the heart failure related biomarkers NT-proBNP, ST-2, galectin-3 and hs-TnI.PATIENTS & METHODS: We included 157 patients with resistant hypertension undergoing RDN. Blood sampling was performed before and 6 months after RDN.RESULTS: Six months after RDN systolic blood pressure (BP) was reduced by 24 mmHg. Biomarker concentrations were not changed after RDN, except a small increase of hs-TnI by 0.3 pg/ml. In individuals with high baseline BP, we observed a BP reduction of 45 mmHg and a decrease of hs-TnI concentrations by 1.2 pg/ml.CONCLUSION: In this multicenter analysis RDN did significantly reduce systolic BP. However, NT-proBNP, ST-2, galectin-3 and hs-TnI did not correspond to BP reduction 6 months after RDN.",
keywords = "Aged, Biomarkers/blood, Blood Pressure/physiology, Echocardiography, Female, Galectin 3/blood, Heart Failure/complications, Humans, Hypertension/complications, Hypertrophy, Left Ventricular/diagnostic imaging, Interleukin-1 Receptor-Like 1 Protein/blood, Kidney/innervation, Male, Middle Aged, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Pulse Wave Analysis, Troponin I/blood",
author = "Neumann, {Johannes Tobias} and Sebastian Ewen and Kai Mortensen and Holger Nef and Tanja Zeller and Francisco Ojeda and Karsten Sydow and Felix Mahfoud and Michael B{\"o}hm and Christian Hamm and Oliver D{\"o}rr and Stefan Blankenberg",
year = "2016",
month = aug,
doi = "10.2217/bmm-2016-0098",
language = "English",
volume = "10",
pages = "841--851",
journal = "BIOMARK MED",
issn = "1752-0363",
publisher = "Future Medicine Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension

AU - Neumann, Johannes Tobias

AU - Ewen, Sebastian

AU - Mortensen, Kai

AU - Nef, Holger

AU - Zeller, Tanja

AU - Ojeda, Francisco

AU - Sydow, Karsten

AU - Mahfoud, Felix

AU - Böhm, Michael

AU - Hamm, Christian

AU - Dörr, Oliver

AU - Blankenberg, Stefan

PY - 2016/8

Y1 - 2016/8

N2 - AIM: This multicenter study investigated the effect of renal denervation therapy (RDN) on the heart failure related biomarkers NT-proBNP, ST-2, galectin-3 and hs-TnI.PATIENTS & METHODS: We included 157 patients with resistant hypertension undergoing RDN. Blood sampling was performed before and 6 months after RDN.RESULTS: Six months after RDN systolic blood pressure (BP) was reduced by 24 mmHg. Biomarker concentrations were not changed after RDN, except a small increase of hs-TnI by 0.3 pg/ml. In individuals with high baseline BP, we observed a BP reduction of 45 mmHg and a decrease of hs-TnI concentrations by 1.2 pg/ml.CONCLUSION: In this multicenter analysis RDN did significantly reduce systolic BP. However, NT-proBNP, ST-2, galectin-3 and hs-TnI did not correspond to BP reduction 6 months after RDN.

AB - AIM: This multicenter study investigated the effect of renal denervation therapy (RDN) on the heart failure related biomarkers NT-proBNP, ST-2, galectin-3 and hs-TnI.PATIENTS & METHODS: We included 157 patients with resistant hypertension undergoing RDN. Blood sampling was performed before and 6 months after RDN.RESULTS: Six months after RDN systolic blood pressure (BP) was reduced by 24 mmHg. Biomarker concentrations were not changed after RDN, except a small increase of hs-TnI by 0.3 pg/ml. In individuals with high baseline BP, we observed a BP reduction of 45 mmHg and a decrease of hs-TnI concentrations by 1.2 pg/ml.CONCLUSION: In this multicenter analysis RDN did significantly reduce systolic BP. However, NT-proBNP, ST-2, galectin-3 and hs-TnI did not correspond to BP reduction 6 months after RDN.

KW - Aged

KW - Biomarkers/blood

KW - Blood Pressure/physiology

KW - Echocardiography

KW - Female

KW - Galectin 3/blood

KW - Heart Failure/complications

KW - Humans

KW - Hypertension/complications

KW - Hypertrophy, Left Ventricular/diagnostic imaging

KW - Interleukin-1 Receptor-Like 1 Protein/blood

KW - Kidney/innervation

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain/blood

KW - Peptide Fragments/blood

KW - Pulse Wave Analysis

KW - Troponin I/blood

U2 - 10.2217/bmm-2016-0098

DO - 10.2217/bmm-2016-0098

M3 - SCORING: Journal article

C2 - 27428075

VL - 10

SP - 841

EP - 851

JO - BIOMARK MED

JF - BIOMARK MED

SN - 1752-0363

IS - 8

ER -